Literature DB >> 8200365

Evaluation of selected prognostic factors in ovarian cancer.

P Roszkowski1, Z Wronkowski, J Szamborski, M Romejko.   

Abstract

Among the group of 367 women with ovarian cancer, 11 prognostic factors were examined. Eight of the factors had an important prognostic value regarding the longterm (5 and 10 years) survivals of ovarian cancer patients. There were the following significant prognostic factors: histological type, the degree of differentiation of the tumour, clinical stage, ascites, overgrowth of the capsule, or infiltration of the ovary surface, irregular shape of the tumour, cancer in both ovaries, and solid type of the tumour. The best prognosis was obtained for patients with mucous type of cancer (53.3%-5 and 26.7%-10 years survival). The poorest prognosis was obtained for the group of patients with undifferentiated cancers, respectively, 11.8 and 3.6%.

Entities:  

Mesh:

Year:  1993        PMID: 8200365

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  6 in total

1.  Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.

Authors:  Satoshi Tsunetoh; Yoshito Terai; Hiroshi Sasaki; Akiko Tanabe; Yoshimichi Tanaka; Tatsuharu Sekijima; Satoe Fujioka; Hiroshi Kawaguchi; Masanori Kanemura; Yoshiki Yamashita; Masahide Ohmichi
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

Review 2.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

Authors:  Samar Masoumi Moghaddam; Afshin Amini; David L Morris; Mohammad H Pourgholami
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

3.  Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination.

Authors:  J M Xanthopoulos; A E Romano; S K Majumdar
Journal:  J Biomed Biotechnol       Date:  2005

4.  Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.

Authors:  Hiroshi Kawaguchi; Yoshito Terai; Akiko Tanabe; Hiroshi Sasaki; Masaaki Takai; Satoe Fujiwara; Keisuke Ashihara; Yoshimichi Tanaka; Tomohito Tanaka; Satoshi Tsunetoh; Masanori Kanemura; Masahide Ohmichi
Journal:  J Ovarian Res       Date:  2014-04-09       Impact factor: 4.234

5.  CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.

Authors:  Kiyoko Nakamura; Yoshito Terai; Akiko Tanabe; Yoshihiro J Ono; Masami Hayashi; Kazuya Maeda; Satoe Fujiwara; Keisuke Ashihara; Michihiko Nakamura; Yoshimichi Tanaka; Tomohito Tanaka; Satoshi Tsunetoh; Hiroshi Sasaki; Masahide Ohmichi
Journal:  Oncol Rep       Date:  2017-04-19       Impact factor: 3.906

Review 6.  Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma.

Authors:  Maria V Barbolina
Journal:  Cancers (Basel)       Date:  2018-11-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.